Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin

This publication has 21 references indexed in Scilit:

• Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines
  European Journal Of Cancer, 2000
• Preclinical and clinical overview of the novel platinum complex, ZD0473 (cis-amminedichloro[2-methylpyridine] platinum[II])
  Lung Cancer, 2000
• Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells
  Oncogene, 2000
• Oxaliplatin or Paclitaxel in Patients With Platinum-Pretreated Advanced Ovarian Cancer: A Randomized Phase II Study of the European Organization for Research and Treatment of Cancer Gynecology Group
  Journal of Clinical Oncology, 2000
• New Developments and Approaches in the Platinum Arena
  Drugs, 2000
• Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.
  Journal of Clinical Oncology, 1998
• In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473
  British Journal of Cancer, 1998
• Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel
  Biochemical Pharmacology, 1996
• Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
  Annals of Oncology, 1996
• The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines
  British Journal of Cancer, 1991